AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial | Zendy

W. Dobrowsky | Zendy; NagrajG Huigol | Zendy; RanapalaS Jayatilake | Zendy; Noor-I-Alam Kizilbash | Zendy; Sait Okkan | Zendy; TsutomuV Kagiya | Zendy; Hideo Tatsuzaki | Zendy

Open Access

AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial

Author(s) -

W. Dobrowsky,

NagrajG Huigol,

RanapalaS Jayatilake,

Noor-I-Alam Kizilbash,

Sait Okkan,

TsutomuV Kagiya,

Hideo Tatsuzaki

Publication year - 2005

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.16705

Subject(s) - medicine , radiation therapy , external beam radiotherapy , brachytherapy , cervical cancer , surgery , randomized controlled trial , stage (stratigraphy) , cancer , urology , nuclear medicine , paleontology , biology

AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research